What second-line therapy would you offer a patient with metastatic colon cancer with Her2 IHC 3+ amplification and KRAS G12D mutation whose disease progressed on FOLFOX?  

This is a rare but interesting situation since HER2 IHC 3+ is only found in <3% metastatic colorectal cancer (mCRC) while KRAS G12D mutation is about 12% in the mCRC population. This combination is quite uncommon. The best evidence would be from the DESTINY-CRC02 (Raghav et al., PMID 39116902), w...